PARP Inhibitors as Initial Treatment for Ovarian Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 10/30/2019 10:47 AM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer 10/29/2019 In three large clinical trials of women with newly diagnosed ovarian cancer, treatment with a PARP inhibitor as first-line therapy, maintenance therapy, or both, extended the length of time before participants’ cancers came back or got worse.
